OR Forum—A POMDP approach to personalize mammography screening decisions
Breast cancer is the most common nonskin cancer and the second leading cause of cancer
death in US women. Although mammography is the most effective modality for breast cancer …
death in US women. Although mammography is the most effective modality for breast cancer …
Navigational Bronchoscopy With Biopsy Versus Computed Tomography—guided Biopsy for the Diagnosis of a Solitary Pulmonary Nodule: A Cost-Consequences …
CR Dale, DK Madtes, VS Fan, JA Gorden… - … of bronchology & …, 2012 - journals.lww.com
Background: Solitary pulmonary nodules (SPNs) are frequent and can be malignant. Both
computed tomography-guided biopsy and electromagnetic navigational bronchoscopy …
computed tomography-guided biopsy and electromagnetic navigational bronchoscopy …
[HTML][HTML] Online tool to guide decisions for BRCA1/2 mutation carriers
Purpose Women with BRCA1 or BRCA2 (BRCA1/2) mutations must choose between
prophylactic surgeries and screening to manage their high risks of breast and ovarian …
prophylactic surgeries and screening to manage their high risks of breast and ovarian …
Cost effectiveness of gene expression profiling for early stage breast cancer: A decision‐analytic model
BACKGROUND: Gene expression profiling (GEP) is being used increasingly for risk
stratification to identify women with lymph node‐negative, estrogen receptor‐positive, early …
stratification to identify women with lymph node‐negative, estrogen receptor‐positive, early …
Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer
Background. Among women with surgically removed, high-risk HER-2/neu-positive breast
cancer, trastuzumab has demonstrated significant improvements in disease-free and overall …
cancer, trastuzumab has demonstrated significant improvements in disease-free and overall …
[HTML][HTML] Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen-or progesterone-receptor …
Background A 21-gene recurrence score (RS) assay may inform adjuvant systematic
treatment decisions in women with early stage breast cancer. We sought to investigate the …
treatment decisions in women with early stage breast cancer. We sought to investigate the …
Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor …
M Kondo, SL Hoshi, H Ishiguro, M Toi - Breast cancer research and …, 2012 - Springer
The 70-gene prognosis-signature is validated as a good predictor of recurrence for hormone
receptor-positive (ER+), lymph node-negative (LN−), human epidermal growth factor …
receptor-positive (ER+), lymph node-negative (LN−), human epidermal growth factor …
Q‐TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer
PK Corey‐Lisle, R Peck, P Mukhopadhyay, L Orsini… - Cancer, 2012 - Wiley Online Library
BACKGROUND: Combination therapy with ixabepilone and capecitabine (cape) is
approved for use in patients with locally advanced/metastatic breast cancer that is resistant …
approved for use in patients with locally advanced/metastatic breast cancer that is resistant …
[HTML][HTML] Health state utility assessment for breast cancer
Abstract Objectives 1) To develop both English and Chinese versions of the descriptions of
health states describing different stages of breast cancer and different adverse effects …
health states describing different stages of breast cancer and different adverse effects …
Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women
BACKGROUND: Recommendations about funding of interventions through the full spectrum
of the disease often have been made in isolation. The authors of this report optimized …
of the disease often have been made in isolation. The authors of this report optimized …